10-K: STAAR Surgical Reports Fiscal Year 2024 Results Amidst China Market Challenges

STAAR Surgical's fiscal year 2024 saw a revenue decrease and net loss, primarily due to a significant decline in ICL sales in China, impacting overall financial performance.

Summary

• STAAR Surgical reported a 3% decrease in net sales for fiscal year 2024, totaling $313.9 million compared to $322.4 million in fiscal 2023.
• The company incurred a net loss of $20.2 million in fiscal 2024, a stark contrast to the net income of $21.3 million in fiscal 2023.
• A significant decline in ICL sales in China during the fourth quarter of 2024 heavily impacted the company's financial results.
• Macroeconomic conditions and weak consumer consumption in China contributed to fluctuating demand for ICL procedures.
• The company did not recognize revenue on a $27.5 million ICL order to a China distributor due to extended payment terms and concerns about collectability.
• Elevated inventory levels held by China distributors, resulting from lower-than-expected procedural volumes, are expected to impact sales in the first half of fiscal 2025.
• The company anticipates minimal China ICL sales in the first half of fiscal 2025 due to sufficient in-country inventory held by distributors.
• STAAR plans to navigate macroeconomic challenges in China and focus on surgeon education, strategic collaborations, and product innovation to drive future growth.
• The company's strategic imperatives for 2025 include supporting the business in China, increasing strategic collaborations, enhancing systems and tools, driving awareness of ICL procedures, and investing in product innovation.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing investments in innovation and strategic initiatives, the negative financial results and challenges in the China market weigh heavily on the overall outlook.

Positives

• The company is focused on surgeon education and training through initiatives like STAAR University and the EVO Experience Center.
• STAAR is investing in enhanced systems and tools to improve ordering and fulfillment processes.
• The company plans to continue driving awareness of ICL procedures and investing in product innovation.
• The company is expanding its manufacturing capabilities in Nidau, Switzerland.
• The company has a cross-functional climate risk committee to identify climate change risks and reduce environmental impact.
• The company has invested in solar photovoltaic panels at three locations in California to reduce energy and waste.

Negatives

• The company reported a decrease in revenue and a net loss in fiscal 2024.
• ICL sales in China experienced a significant decline in the fourth quarter of 2024.
• The company did not recognize revenue on a $27.5 million ICL order to a China distributor due to extended payment terms.
• Distributors in China held elevated levels of ICL product inventory as of December 27, 2024.
• The company anticipates minimal China ICL sales in the first half of fiscal 2025.
• The company is vulnerable to any loss of use of its principal manufacturing facility in Monrovia, California.

Risks

• The company's reliance on independent distributors in international markets exposes it to commercial and other risks.
• A slowdown or disruption to the Chinese economy or worsening trade relations between the U.S. and China could materially impact the company's business and results of operations.
• Unfavorable economic conditions or negative publicity concerning complications of laser eye surgery, or medical devices in general, could hurt sales of the company's refractive products.
• Disruptions in the company's supply chain or failure to adequately forecast product demand could result in significant delays or lost sales.
• Because the company's business is global, its sales and profits may fluctuate or decline in response to changes in foreign currency exchange rates and/or other international risks, including tariffs.
• Changes in the company's effective tax rate or additional tax liabilities could adversely impact its net income.
• The company is vulnerable to any loss of use of its principal manufacturing facility.
• Public health crises, political crises, and other catastrophic events or other events outside of the company's control may impact its business.
• The loss of key employees, or the company's inability to recruit, hire and retain skilled and experienced personnel, could negatively impact its ability to effectively manage and expand its business.
• The company competes with much larger companies and low-cost Asian manufacturers.
• The company could experience losses due to product liability claims.
• The company's defined benefit pension plans are currently underfunded and it may be subject to significant increases in pension benefit obligations under those pension plans.
• The company's activities involve hazardous materials, emissions, and use of an irradiator and may subject it to environmental liability.
• Data corruption, cyber-based attacks or network security breaches and/or noncompliance with data protection and privacy regulations could negatively impact the company's operations.
• Acquisitions of technologies, products, and businesses could disrupt the company's operations, involve increased expenses and present risks not contemplated at the time of the transactions.
• If the company is not able to manage growth successfully, it could adversely affect its business, financial condition, and results of operations.
• Corporate responsibility, specifically related to environmental, social and governance (ESG) matters, may impose additional costs, expose the company to reputational and emerging areas of risks, and could negatively affect its business.
• Climate changes and extreme weather conditions could negatively affect the company's business.
• Unless the company keeps pace with advances in its industry and persuade physicians to adopt its new products, its sales will not grow and may decline.
• Resources devoted to research and development may not yield new ophthalmic products that achieve regulatory approval or commercial success.
• The company may be required to conduct extensive clinical trials to demonstrate safety and effectiveness of new or enhanced ophthalmic products, such clinical trials are expensive, complex, can take years to complete, and have highly uncertain outcomes.
• Complying with government regulation substantially increases the cost of developing, manufacturing and selling the company's ophthalmic products.
• The company depends on proprietary technology, but its intellectual property protections may be limited.
• The company may not successfully replace its existing products, including those that lose or have lost patent protection.
• The company is subject to extensive government regulation worldwide, which increases its costs and could prevent it from selling its products.
• Laws pertaining to healthcare fraud and abuse could materially adversely affect the company's business, financial condition, and results of operations.
• If the company recalls a product, the cost and damage to its reputation could harm its business.
• Changes in U.S. FDA or international regulations related to product approval, including those that apply retroactively, could make the company less competitive and harm its business.
• If the company's products cause or contribute to a death or a serious injury, it may face voluntary corrective actions, agency enforcement actions and harm to its results.
• If the company modifies its products, it may have to obtain new marketing clearances or approvals or may have to cease marketing or recall the modified products until clearances or approvals are obtained.
• Non-compliance with anti-corruption laws could lead to penalties or harm the company's reputation.
• The company's failure to comply with the requirements of the U.S. FDA or other regulators can result in civil and criminal fines, the recall of products, the total or partial suspension of manufacturing or distribution, seizure of products, injunctions, lawsuits, failure to obtain approval of pending product applications, withdrawal of existing product approvals, exclusion from participation in government healthcare programs and other sanctions.
• The market price of the company's common stock has been and will likely continue to be volatile.
• Because the company does not intend to pay dividends, stockholders will benefit from an investment in its common stock only if it appreciates in value.
• The company's Certificate of Incorporation and Bylaws, anti-takeover provisions of Delaware law, and contractual provisions could delay or prevent an acquisition or sale of the company.
• Ownership of the company's common stock is concentrated among a few investors, which may affect the ability of a third party to acquire control of it.
• Future sales of the company's common stock could reduce its stock price.

Future Outlook

The company expects volatility in surgical procedure volumes in China to continue until consumer confidence stabilizes and improves. Minimal China ICL sales are anticipated in the first half of fiscal 2025. The company plans to adjust production output based on forecasted demand and optimize inventory levels.

Management Comments

• A key focus in 2025 will be supporting our business in China as we work to navigate the macroeconomic challenges and position the Company for growth once the market recovers.
• Across our markets, we recognize the need to further educate and train ophthalmic surgeons about our ICLs and our ICL procedure.
• In 2025, we intend to increase the number of strategic collaborations with leading refractive surgeons and practices in the U.S. to collaborate on marketing, training and education activities.
• In 2025, we will also continue to drive awareness of the ICL procedure to reach even more potential patients and effectively communicate the clinical benefits of our ICLs.
• While we work to launch our existing product portfolio in attractive global markets, we also intend to continue to invest in product innovation in 2025.

Industry Context

The ophthalmic surgical product market is intensely competitive, driven by technological innovation and regulatory approvals. STAAR Surgical competes with other elective surgical procedures like laser vision correction (e.g., LASIK) and faces competition from larger companies with greater resources, as well as emerging low-cost Asian manufacturers.

Comparison to Industry Standards

• Alcon, Johnson & Johnson, Bausch Health Companies, and Carl Zeiss Meditec AG are major competitors in the laser vision correction market, possessing greater financial, technical, marketing, and distribution resources than STAAR Surgical.
• Phakic implants from Biotech Vision Care, Care Group, Eyebright, and Ophtec also compete with STAAR Surgical's ICL technology.
• Competitors from Asia are entering the market with low-cost versions of implantable contact lenses, increasing competition.
• According to Market Scope, LLC, approximately 5.2 million refractive procedures were expected to be performed worldwide in 2024, primarily laser vision procedures.

Stakeholder Impact

• Shareholders: The decrease in revenue and net loss may negatively impact shareholder value.
• Employees: The company's performance may affect employee compensation and job security.
• Customers: The company's focus on innovation and training may lead to improved products and services for customers.
• Suppliers: The company's supply chain may be affected by macroeconomic conditions and trade relations.
• Creditors: The company's financial performance may impact its ability to meet its obligations to creditors.

Next Steps

• The company intends to increase the number of strategic collaborations with leading refractive surgeons and practices in the U.S. to collaborate on marketing, training and education activities.
• The company plans to leverage its new EVO Experience Center at its headquarters in Lake Forest, CA, to conduct additional hands-on training and education in lens-based vision correction.
• The company will continue to drive awareness of the ICL procedure to reach even more potential patients and effectively communicate the clinical benefits of our ICLs.
• The company intends to continue to invest in product innovation in 2025.

Key Dates

Keywords

ICL, STAAR Surgical, Financial Results, China, Net Sales, Net Loss, Ophthalmic, Revenue, Collamer, EVO